Adjuvant HPV Vaccination and Survival in Oropharyngeal Squamous Cell Carcinoma: An Exploratory Analysis of a Real‐World Database
- 1Caruso Department of Otolaryngology–Head and Neck Surgery Keck School of Medicine of University of Southern California Los Angeles California USA
- 2Keck School of Medicine of the University of Southern California Los Angeles California USA
- 3Department of Otolaryngology–Head and Neck Surgery University of California, Irvine Orange California USA
Abstract
Objective Childhood HPV vaccination reduces oropharyngeal cancer (OPC) incidence, but evidence regarding vaccination after HPV exposure or OPC diagnosis remains limited. While benefits are documented in cervical dysplasia, anogenital cancers, and laryngeal papillomatosis, the impact on OPC outcomes is unknown. Methods Using the prospective TrinetX database, OPC patients were stratified by HPV vaccination status. Vaccinated patients were divided into three cohorts: vaccinated before OPC diagnosis, within 1 year after diagnosis, and at any timepoint. Cohorts were propensity‐matched with unvaccinated controls by age, race, ethnicity, sex, and cancer stage. Survival outcomes were assessed at 2, 5, and > 5 years post‐diagnosis using absolute risk reduction and Kaplan–Meier analyses. Results Propensity matching yielded 162 patients vaccinated at any time, 24 vaccinated within 1 year post‐diagnosis, and 79 vaccinated pre‐diagnosis, with equal matched controls showing no demographic differences. Women predominated among those vaccinated before OPC diagnosis (73%), while men comprised 80% of those vaccinated after diagnosis. HPV vaccination was associated with improved overall survival at 2 years (97% vs. 91%, p = 0.29), 5 years (97% vs. 89%, p = 0.019), and > 5 years (93% vs. 74%, p = 0.0003) for the vaccinated‐anytime cohort versus never‐vaccinated patients, translating to 5.14% absolute risk reduction at 5 years. Trends persisted but lacked statistical significance in pre‐ and post‐diagnosis vaccination subgroups. Conclusion HPV vaccination after HPV exposure was associated with improved survival in OPC patients. However, imperfect HPV ascertainment, small vaccinated cohorts, and potential selection bias, including a healthy vaccinee effect, preclude causal inference, and this association should not be interpreted as evidence of a therapeutic effect. Prospective and randomized clinical trials are needed to determine whether adjuvant HPV vaccination confers a true survival benefit in OPC. Given the low morbidity of therapy and high potential survival impact, a clinical trial is warranted. Level of Evidence 3.
Related
- Clinical Profile and Survival of Oropharyngeal Squamous-Cell Carcinoma in a Region of Northern Spain with a Low HPV-Attributable Fraction: A Retrospective Cohort Study
- Body Mass Index and Nutritional Dynamics as Predictors of Survival in Patients with Oropharyngeal Squamous Cell Carcinoma Undergoing Chemoradiation
- The crucial question: does adjuvant radiotherapy confer a survival benefit in pN1 oral squamous cell carcinoma (OSCC)? - A retrospective analysis.
- Does the Disease-free Survival Benefit of Adding Belzutifan to Adjuvant Pembrolizumab Persist Beyond the Planned Treatment Period? A Reconstructed Individual Patient Data Analysis of Phase 3 Renal Cell Carcinoma Trials
- Smoking exposure and overall survival in nasopharyngeal carcinoma: a multicenter cohort from non-endemic northern China with an exploratory meta-analysis
BibTeX
@article{kim2026adjuvant,
title = {{Adjuvant HPV Vaccination and Survival in Oropharyngeal Squamous Cell Carcinoma: An Exploratory Analysis of a Real‐World Database}},
author = {Mary Elizabeth Kim and Kevin Herrera and Albert Han and Kevin Hur and Niels Kokot and Mark S. Swanson},
journal = {Laryngoscope Investigative Otolaryngology},
year = {2026},
month = oct,
doi = {10.1002/lio2.70573},
url = {https://doi.org/10.1002/lio2.70573},
note = {CC BY},
}
RIS
TY - JOUR
TI - Adjuvant HPV Vaccination and Survival in Oropharyngeal Squamous Cell Carcinoma: An Exploratory Analysis of a Real‐World Database
AU - Mary Elizabeth Kim
AU - Kevin Herrera
AU - Albert Han
AU - Kevin Hur
AU - Niels Kokot
AU - Mark S. Swanson
PY - 2026
DA - 2026/10/28
JO - Laryngoscope Investigative Otolaryngology
DO - 10.1002/lio2.70573
UR - https://doi.org/10.1002/lio2.70573
AB - Objective Childhood HPV vaccination reduces oropharyngeal cancer (OPC) incidence, but evidence regarding vaccination after HPV exposure or OPC diagnosis remains limited. While benefits are documented in cervical dysplasia, anogenital cancers, and laryngeal papillomatosis, the impact on OPC outcomes is unknown. Methods Using the prospective TrinetX database, OPC patients were stratified by HPV vaccination status. Vaccinated patients were divided into three cohorts: vaccinated before OPC diagnosis, within 1 year after diagnosis, and at any timepoint. Cohorts were propensity‐matched with unvaccinated controls by age, race, ethnicity, sex, and cancer stage. Survival outcomes were assessed at 2, 5, and > 5 years post‐diagnosis using absolute risk reduction and Kaplan–Meier analyses. Results Propensity matching yielded 162 patients vaccinated at any time, 24 vaccinated within 1 year post‐diagnosis, and 79 vaccinated pre‐diagnosis, with equal matched controls showing no demographic differences. Women predominated among those vaccinated before OPC diagnosis (73%), while men comprised 80% of those vaccinated after diagnosis. HPV vaccination was associated with improved overall survival at 2 years (97% vs. 91%, p = 0.29), 5 years (97% vs. 89%, p = 0.019), and > 5 years (93% vs. 74%, p = 0.0003) for the vaccinated‐anytime cohort versus never‐vaccinated patients, translating to 5.14% absolute risk reduction at 5 years. Trends persisted but lacked statistical significance in pre‐ and post‐diagnosis vaccination subgroups. Conclusion HPV vaccination after HPV exposure was associated with improved survival in OPC patients. However, imperfect HPV ascertainment, small vaccinated cohorts, and potential selection bias, including a healthy vaccinee effect, preclude causal inference, and this association should not be interpreted as evidence of a therapeutic effect. Prospective and randomized clinical trials are needed to determine whether adjuvant HPV vaccination confers a true survival benefit in OPC. Given the low morbidity of therapy and high potential survival impact, a clinical trial is warranted. Level of Evidence 3.
SN - 2378-8038
ER -